The contribution of enteroinsular hormones to the pathogenesis of type 2 diabetes mellitus

Current Diabetes Reports

Volumn 10, Issue 3, 2010, Pages 192-198

  Diab, Dima L ^a   D'Alessio, David A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

DPP 4; Enteroinsular axis; GIP; GLP 1; Glucagon; Incretins; Insulin; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; TRANSCRIPTION FACTOR 7 LIKE 2; VILDAGLIPTIN;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLYCEMIC CONTROL; HORMONE ACTION; HORMONE RELEASE; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN;

EID: 77956394651     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0114-6     Document Type: Review

References (58)

1. Drucker D: The biology of incretin hormones. Cell Metab 2006, 3:153-165.
2. D'Alessio D: Incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1. In Ellenberg and Rifkin's Diabetes Mellitus, edn 6. Edited by Porte J, Sherwin R, Baron A. New York: McGraw-Hill; 2002:85-96
3. Anini Y, Brubaker PL: Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 2003, 144:3244-3250.
4. Gribble FM: Targeting GLP-1 release as a potential strategy for the therapy of type 2 diabetes. Diabet Med 2008, 25:889-894. This is a comprehensive review of GLP-1, its different physiologic effects, the mechanisms underlying GLP-1 secretion, and therapeutic implications in the treatment of type 2 diabetes.
5. Greenfield JR, Farooqi IS, Keogh JM, et al.: Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009, 89:105-113. This study compared the incretin response to oral glutamine in eight lean, eight obese nondiabetic, and eight obese subjects with type 2 diabetes or IGT. Glutamine was found to increase circulating GLP-1, GIP, and insulin concentrations in all three groups.
6. Nauck MA, Baller B, Meier JJ: Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004, 53(Suppl 3):S190-S196.
7. Schirra J, Sturm K, Leicht P, et al.: Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998, 101:1421-1430.
8. Schirra J, Nicolaus M, Roggel R, et al.: Endogenous glucagonlike peptide 1 controls endocrine pancreatic secretion and antropyloro- duodenal motility in humans. Gut 2006, 55:243-251.
9. Meier JJ, Gallwitz B, Siepmann N, et al.: Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
10. Meier JJ, Deacon CF, Schmidt WE, et al.: Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 2007, 50: 806-813. This study looked at 16 firstdegree relatives of patients with type 2 diabetes and 10 controls during oral glucose tolerance test (OGTT) and IV glucose infusions. Glucagon levels were significantly suppressed in both experiments but the suppression was more pronounced during the IV glucose infusion. The differences between glucagon responses to oral and IV glucose correlated with GIP and GLP-1 levels. There were no differences in glucagon levels between the groups.
11. Dean AM, Nguyen NQ, Stevens JE, et al.: Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010, 95:215-221. Ten healthy fasted subjects were randomized to receive a GLP-1 antagonist exendin(9-39) infusion or placebo. It was found that the GLP-1 antagonist accelerated gastric emptying and increased the glycemic response to a mashed potato meal, suggesting that GLP-1 plays a physiologic role to slow gastric emptying in health, which impacts on glucose absorption and postprandial glycemia.
12. Tang-Christensen M, Larsen PJ, Goke R, et al.: Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996, 271(4 Pt 2): R848-R856.
13. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon-and insulin-producing cells. Diabetes 1999, 48: 2358-366.
14. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
15. Abraham EJ, Leech CA, Lin JC, et al.: Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic isletderived progenitor cells into insulin-producing cells. Endocrinology 2002, 143:3152-3161.
16. Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
17. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH: Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970, 283:109-115.
18. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
19. Nauck MA, El-Ouaghlidi A, Gabrys B, et al.: Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004, 122:209-217.
20. Meier JJ, Gallwitz B, Askenas M, et al.: Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 2005, 48:1872-1881.
21. Cypryk K, Vilsboll T, Nadel I, et al.: Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus. Gynecol Endocrinol 2007, 23:58-62. Thirteen women with gestational diabetes and 13 controls were evaluated during an OGTT. No significant differences in GIP and GLP-1 responses were found between the two groups at any time of the study.
22. Muscelli E, Mari A, Casolaro A, et al.: Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348. This study examined the incretin effect by performing oral and IV glucose tolerance tests in patients with normal glucose tolerance, IGT, and type 2 diabetes. It was found that glucose intolerance and obesity impair the incretin effect independently of one another and in an additive manner. Furthermore, glucagon suppression was found to be blunted in diabetic patients.
23. Muscelli E, Mari A, Natali A, et al.: Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.AmJ Physiol EndocrinolMetab 2006, 291: E1144-E1150.
24. Laakso M, Zilinskaite J, Hansen T, et al.: Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 2008, 51:502-511. This study assessed incretin levels in subjects with impaired fasting glucose as well as IGT. GLP-1 but not GIP levels were found to be reduced in individuals with abnormal glucose tolerance.
25. Toft-Nielsen MB, Damholt MB, Madsbad S, et al.: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717-3723.
26. Vollmer K, Holst JJ, Baller B, et al.: Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687. Seventeen patients with mild type 2 diabetes, 17 with IGT, and 14 controls were assessed during an OGTT and mixed-meal challenge. GLP-1 levels were found to be the same in all three groups in both experiments. Also, GIP levels were similar after OGTT and there were no differences in integrated GIP levels after the meal.
27. Vilsboll T, Krarup T, Deacon CF, et al.: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
28. Meier JJ, Nauck MA: Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2008, 4:606-607. This is a commentary summarizing the clinical data assessing GLP-1 secretion in type 2 diabetes and concluding that type 2 diabetes can develop without impairment in GLP-1 secretion, which appears to be a consequence rather than a cause of type 2 diabetes.
29. Vilsboll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
30. Vilsboll T, Agerso H, Lauritsen T, et al.: The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 2006, 137:168-172.
31. Vilsboll T, Krarup T, Madsbad S, Holst JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002, 45:1111-1119.
32. Lynn FC, Thompson SA, Pospisilik JA, et al.: A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 2003, 17:91-93.
33. Xu G, Kaneto H, Laybutt DR, et al.: Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007, 56:1551-1558. Gene expression of incretin receptors was found to be significantly decreased in islets of pancreatectomized hyperglycemic rats, with recovery when glucose levels were normalized. This suggests that this is a likely mechanism contributing to the impaired incretin effects found in diabetes.
34. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
35. Hojberg PV, Zander M, Vilsboll T, et al.: Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 2008, 51:632-640. This study investigated the effects of 4 weeks of near-normalization of blood glucose levels using insulin treatment in nine obese diabetic patients compared with nine controls. It was found that a supraphysiologic dose of GLP-1 enhances ß-cell responses to glucose in patients with type 2 diabetes, and near-normalization of blood glucose levels for 4 weeks further enhances ß-cell sensitivity and improves this effect.
36. Hare KJ, Knop FK, Asmar M, et al.: Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009, 94:4679-4687. This study assessed the effect of GLP-1 infusions on glucagon secretion in 10 diabetic patients as well as healthy controls. There was a dose-dependent stepwise suppression of glucagon secretion in both patients and controls.
37. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB: Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagonlike peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996, 135:425-432.
38. Knop FK, Vilsboll T, Hojberg PV, et al.: The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul Pept 2007, 144:123-130. This study examined the effect of GIP in patients with diabetes secondary to chronic pancreatitis but not requiring insulin. Using hyperglycemic clamps and GIP infusions, it was found that there was a lack of GIP amplification of the late insulin response to IV glucose as glucose tolerance deteriorates in patients with chronic pancreatitis, suggesting that the same may be true for the loss of GIP effect in patients with type 2 diabetes.
39. Knop FK, Vilsboll T, Hojberg PV, et al.: Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007, 56:1951-1959.
40. Vollmer K, Gardiwal H, Menge BA, et al.: Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab 2009, 94:1379-1385. Fifteen nondiabetic individuals participated in euglycemic and hyperglycemic clamps to assess the effects of acute hyperglycemia on the incretin response. It was found that the postprandial increases in GIP and GLP-1 following the administration of a mixed meal were about 50% lower during the experiments with hyperglycemia. Hyperglycemia also elicited a significant delay in gastric emptying.
41. Hojberg PV, Vilsboll T, Rabol R, et al.: Four weeks of nearnormalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52:199-207. This study evaluated the incretin effect in eight obese diabetic patients with poor glycemic control before and after 4 weeks of near-normalization of blood glucose levels using insulin treatment. After 4 weeks, it was found that ß-cell responsiveness to both GLP-1 and GIP improved by a factor of 3 to 4.
42. Knop FK, Vilsboll T, Madsbad S, et al.: Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007, 50:797-805. Glucagon suppression responses were studied during OGTT and IV glucose infusion in 10 diabetic patients and 10 controls; these were found to be significantly attenuated and delayed only in the diabetic patients after oral ingestion of glucose, suggesting that this phenomenon contributes to both the glucose intolerance and reduced incretin effect observed in patients with type 2 diabetes.
43. Florez JC, Jablonski KA, Bayley N, et al.: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355:241-250.
44. Saxena R, Gianniny L, Burtt NP, et al.: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55:2890-2895.
45. Meigs JB, Manning AK, Fox CS, et al.: Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genet 2007, 8(Suppl 1):S16.
46. Grant RW, Moore AF, Florez JC: Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care 2009, 32:1107-1114. This review article focuses on the recent genetic discoveries pertaining to polygenic type 2 diabetes.
47. Schafer SA, Tschritter O, Machicao F, et al.: Impaired glucagonlike peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007, 50:2443-2450. A total of 1110 nondiabetic German participants were genotyped for polymorphisms in TCF7L2 and underwent an OGTT to assess the incretin response. Two hundred and ten participants also underwent an IV glucose tolerance test. It was found that variants of TCF7L2 specifically impair GLP-1- induced insulin secretion, and this was likely due to a defect in GLP-1 signaling as opposed to a reduction in GLP-1 secretion.
48. Nauck MA, Meier JJ: The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Diabetologia 2007, 50:2413-2416.
49. Pilgaard K, Jensen CB, Schou JH, et al.: The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009, 52:1298-1307. In this study, 81 healthy young Danish men underwent genotyping for the T allele of rs7903146 TCF7L2 along with various ß-cell tests. It was found that subjects with this genotype had reduced 24-hour insulin and glucagon concentrations, along with reduced insulin secretion during mixed meal testing and elevated hepatic glucose production.
50. Villereal DT, Robertson H, Bell GI, et al.: TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010, 59:479-485. This study evaluated eight subjects with risk-conferring TCF7L2 genotypes (TT or TC at rs7903146) and 10 matched subjects with wild-type genotype (CC). The incretin effect was assessed from ratios of the insulin secretory rates during oral and isoglycemic glucose infusions. ß- Cell responsivity to oral glucose was 50% lower in the group of subjects with risk-conferring TCF7L2 genotypes compared with control subjects. The incretin effect was also reduced by 30% in the at-risk group, suggesting that this genotypic variant affects the risk of type 2 diabetes, at least in part, by modifying the effect of incretins on insulin secretion.
51. Kolterman OG, Kim DD, Shen L, et al.: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
52. Buse JB, Rosenstock J, Sesti G, et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47. This is a 26-week trial comparing once-daily liraglutide with twice-daily exenatide in 233 diabetic patients who were uncontrolled on maximally tolerated doses of metformin, sulfonylurea, or both. This study revealed that liraglutide once a day provided significantly greater improvements in glycemic control than did exenatide twice a day and was generally better tolerated.
53. Vilsboll T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 2009, 45:101-113.
54. Vilsboll T, Brock B, Perrild H, et al.: Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and argininestimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008, 25:152-156.
55. Vilsboll T, Zdravkovic M, Le-Thi T, et al.: Liraglutide, a longacting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30:1608-1610.
56. Klonoff DC, Buse JB, Nielsen LL, et al.: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286. This randomized openlabel trial showed that adjunctive exenatide treatment for at least 3 years in patients with type 2 diabetes resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
57. Kim D, MacConell L, Zhuang D, et al.: Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493. This is a 15-week randomized clinical trial that evaluated the effect of lower and higherdose exenatide LAR administered to 45 diabetic subjects with suboptimal glycemic control on metformin and/or diet and exercise. It was found that subjects receiving exenatide LAR had significant reductions in mean HbA1c compared with placebo, and subjects receiving the higher dose of exenatide LAR also had significant reductions in mean weight compared with the other two groups.
58. Ahren B: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009, 23:487-498. This is an excellent current review of the three available DPP-4 inhibitors that summarizes the results of the clinical studies demonstrating the efficacy and safety data for these agents.